第陸章、参考文獻

metabolism by human liver microsomes is mediated by both
S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol
38:131-137.
Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ,
Boobis AR, Pelkonen O and Raunio H (1997) Expression and
localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell
Mol Biol 16:242-249.
Aoyama T, Gonzalez FJ and Gelboin HV (1989a) Human
cDNA-expressed cytochrome P450 IA2: mutagen activation and substrate
specificity. Molecular Carcinogenesis 2:192-198.
Aoyama T, Gonzalez FJ and Gelboin HV (1989b) Mutagen activation by
cDNA-expressed P(1)450, P(3)450, and P450a. Molecular
Carcinogenesis 1:253-259.
Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V,
Tyndale R, Inaba T, Kalow W, Gelboin HV and et al. (1989c)
Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product
that is differentially expressed in adult human liver. cDNA and deduced
amino acid sequence and distinct specificities of cDNA-expressed hPCN1
and hPCN3 for the metabolism of steroid hormones and cyclosporine.
Journal of Biological Chemistry 264:10388-10395.
321

Arai M, Serizawa N, Terahara A, Tsujita Y, Tanaka M, Masuda H and
Ishikawa S (1988) Pravastatin sodium (CS-514), a novel
cholesterol-lowering agent which inhibits HMG-CoA reductase. Sankyo
Kenkyusho Nempo 40:1-38.
Araya Z and Wikvall K (1999) 6alpha-hydroxylation of
taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human
liver microsomes. Biochim Biophys Acta 1438:47-54.
Arnadottir M, Eriksson LO, Thysell H and Karkas JD (1993) Plasma
concentration profiles of simvastatin
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in
kidney transplant recipients with and without ciclosporin. Nephron
65:410-413.
Austin KL, Mather LE, Philpot CR and McDonald PJ (1980) Intersubject
and dose-related variability after intravenous administration of
erythromycin. Br J Clin Pharmacol 10:273-279.
Backman JT, Kyrklund C, Kivisto KT, Wang JS and Neuvonen PJ (2000)
Plasma concentrations of active simvastatin acid are increased by
gemfibrozil. Clinical Pharmacology & Therapeutics 68:122-129.
Bailey DG, Arnold JM and Spence JD (1994) Grapefruit juice and drugs.
How significant is the interaction? Clin Pharmacokinet 26:91-98.
322

Bailey DG, Bend JR, Arnold JM, Tran LT and Spence JD (1996)
Erythromycin-felodipine interaction: magnitude, mechanism, and
comparison with grapefruit juice. Clinical Pharmacology & Therapeutics
60:25-33.
Bailey DG, Spence JD, Edgar B, Bayliff CD and Arnold JM (1989)
Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med
12:357-362.
Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I,
Guida M, Hopkins PJ, Warner N and Hall J (1999) Population
distribution and effects on drug metabolism of a genetic variant in the 5'
promoter region of CYP3A4. Clin Pharmacol Ther 66:288-294.
Baller D, Gleichmann U, Notohamiprodjo G, Weise R, Holzinger J,
Montanus H, Betker S and Lehmann J (1998) [Improved coronary
vasodilator capacity by drug lipid lowering therapy in patients in the early
stage of coronary atherosclerosis with reduced coronary reserves and
moderate LDL hypercholesteremia]. Z Kardiol 87 Suppl 2:136-144.
Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R and
Lehmann J (1999) Improvement in coronary flow reserve determined by
positron emission tomography after 6 months of cholesterol-lowering
therapy in patients with early stages of coronary atherosclerosis.
Circulation 99:2871-2875.
323

Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS and Guengerich FP
(1986) Isolation and sequence determination of a cDNA clone related to
human cytochrome P-450 nifedipine oxidase. Proc Natl Acad Sci U S A
83:8064-8068.
Benet LZ, Kroetz DL and Sheiner LB (1996) Pharmackinetics: The
dynamics of drug absorption, distribution and elimination. Hardman JG,
Limbird LE, Molinoff PB. et al., editors. Goodman and Gilmans the
pharmacological basis of therapeutics, 9th ed. New York (NY);
McGraw-Hill, 1996:3-29.
Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J,
Gauthier JC, Beaune P, Pompon D and et al. (1993) Metabolic activation
of the nitroaromatic antiandrogen flutamide by rat and human
cytochromes P-450, including forms belonging to the 3A and 1A
subfamilies. J Pharmacol Exp Ther 265:366-372.
Black AE, Hayes RN, Roth BD, Woo P and Woolf TF (1999) Metabolism
and excretion of atorvastatin in rats and dogs. Drug Metab Dispos
27:916-923.
Black AE, Sinz MW, Hayes RN and Woolf TF (1998) Metabolism and
excretion studies in mouse after single and multiple oral doses of the
3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug
Metab Dispos 26:755-763.
324

Black D, Kunze K, Wienkers L, Gidal B, Seaton T, McDonnell N, Evans
J, Bauwens J and Trager W (1996) Warfarin-Fluconazole, V.A.
Metabolically Based Drug Interaction: In Vivo Studies. Drug Metab
Dispos 24:422-428.
Bladeren Pv (2000) Glutathione conjugation as a bioactivation reaction.
Chemo-Biological Interaction 129:61-76.
Blychert E, Edgar B, Elmfeldt D and Hedner T (1991) A population study
of the pharmacokinetics of felodipine. Br J Clin Pharmacol 31:15-24.
Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke
J and Radtke M (1997) Metabolism of cerivastatin by human liver
microsomes in vitro. Characterization of primary metabolic pathways and
of cytochrome P450 isozymes involved. Drug Metab Dispos 25:321-331.
Boberg M, Angerbauer R, Kanhai WK, Karl W, Kern A, Radtke M and
Steinke W (1998) Biotransformation of cerivastatin in mice, rats, and
dogs in vivo. Drug Metab Dispos 26:640-652.
Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ,
Eijdems EW, Baas F and Zaman GJ (1993) Classical and novel forms of
multidrug resistance and the physiological functions of P-glycoproteins in
mammals. Pharmacology & Therapeutics 60:289-299.
325

Botsch S, Gautier JC, Beaune P, Eichelbaum M and Kroemer HK (1993)
Identification and characterization of the cytochrome P450 enzymes
involved in N-dealkylation of propafenone: molecular base for interaction
potential and variable disposition of active metabolites. Mol Pharmacol
43:120-126.
Bottorff M and Hansten P (2000) Long-term safety of hepatic
hydroxymethyl glutaryl coenzyme A reductase inhibitors-the role of
metabolism:monograph for physicians[review]. Arch Intern Med
160:2273-2280.
Brandt E, Heymann E and Mentlein R (1980) Selective inhibition of rat
liver carboxylesterases by various organophosphorus diesters in vivo and
in vitro. Biochem Pharmacol 29:1927-1931.
Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brosen K and
Friedberg T (2002) In vitro investigation of cytochrome P450-mediated
metabolism of dietary flavonoids. Food Chem Toxicol 40:609-616.
Britten C, Baker S, Denis L, Johnson T, Drengler R, Siu L, Duchin K,
Kuhn J and Rowinsky E (2000) Oral Paclitaxel and Concurrent
Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to
Paclitaxel. Clinicla Cancer Research 6:3459.
Britton L, Letassy N and Sirmans S (1994) Managing High Blood
Cholesterol in Patients with Coronary Artery Disease, in Pharmacy Times
326

pp 64-70.
Bronson D, Daniels D, Dixon J, Redick C and Haaland P (1995) Virtual
Kinetics:Using Statistical Experimental Design for Rapid Analysis of
Enzyme Inhibitor Mechanisms. Biochem Pharmacol 50:823-831.
Brosen K and Gram LF (1989a) Clinical significance of the
sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol
36:537-547.
Brosen K and Gram LF (1989b) Quinidine inhibits the 2-hydroxylation of
imipramine and desipramine but not the demethylation of imipramine.
European Journal of Clinical Pharmacology 37:155-160.
Brown MS and Goldstein JL (1986) A receptor-mediated pathway for
cholesterol homeostasis. Science 232:34-47.
Campana C, Regazzi MB, Buggia I and Molinaro M (1996) Clinically
significant drug interactions with cyclosporin. An update. Clin
Pharmacokinet 30:141-179.
Carriere V, Berthou F, Baird S, Belloc C, Beaune P and de Waziers I
(1996) Human cytochrome P450 2E1 (CYP2E1): from genotype to
phenotype. Pharmacogenetics 6:203-211.
327

Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S and
Kannel WB (1986) Incidence of coronary heart disease and lipoprotein
cholesterol levels. The Framingham Study. Jama 256:2835-2838.
Chang TK, Weber GF, Crespi CL and Waxman DJ (1993) Differential
activation of cyclophosphamide and ifosphamide by cytochromes P-450
2B and 3A in human liver microsomes. Cancer Research 53:5629-5637.
Cheng H, Schwartz MS, Vickers S, Gilbert JD, Amin RD, Depuy B, Liu
L, Rogers JD, Pond SM, Duncan CA and et al. (1994) Metabolic
disposition of simvastatin in patients with T-tube drainage. Drug Metab
Dispos 22:139-142.
Cheung NW, Liddle C, Coverdale S, Lou JC and Boyages SC (1996)
Growth hormone treatment increases cytochrome P450-mediated
antipyrine clearance in man. J Clin Endocrinol Metab 81:1999-2001.
Coleman MD, Breckenridge AM and Park BK (1989) Bioactivation of
dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes.
Br J Clin Pharmacol 28:389-395.
Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP and
Maurel P (1989) Metabolism of cyclosporin A. IV. Purification and
identification of the rifampicin-inducible human liver cytochrome P-450
(cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug
Metab Dispos 17:197-207.
328

Cooper D, Levin, S., Narasimhulu, S., Rosenthal, O., Estabrook, R. (1965)
Photochemical Action Spectrum of the Terminal Oxidase of Mixed
Function Oxidase Systems. Science 147:400-402.
Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP and Ferris FL, 3rd
(2003) Histopathology and regression of retinal hard exudates in diabetic
retinopathy after reduction of elevated serum lipid levels. Ophthalmology
110:2126-2133.
Dain JG, Fu E, Gorski J, Nicoletti J and Scallen TJ (1993)
Biotransformation of fluvastatin sodium in humans. Drug Metabolism &
Disposition 21:567-572.
Daly AK, Armstrong M, Monkman SC, Idle ME and Idle JR (1991)
Genetic and metabolic criteria for the assignment of debrisoquine
4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics
1:33-41.
Davies B and Morris T (1993) Physiological parameters in laboratory
animals and humans. Pharm Res 10:1093-1095.
de Waziers I, Cugnenc PH, Yang CS, Leroux JP and Beaune PH (1990)
Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione
transferases in rat and human hepatic and extrahepatic tissues. Journal of
Pharmacology & Experimental Therapeutics 253:387-394.
329

Dietschy JM and Wilson JD (1970a) Regulation of cholesterol
metabolism. New England Journal of Medicine 282:1179-1183.
Dietschy JM and Wilson JD (1970b) Regulation of cholesterol
metabolism. 3. New England Journal of Medicine 282:1241-1249.
Dietschy JM and Wilson JD (1970c) Regulation of cholesterol
metabolism. I. New England Journal of Medicine 282:1128-1138.
Dingemanse J, Schaarschmidt D and van Giersbergen PL (2003)
Investigation of the mutual pharmacokinetic interactions between
bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin
Pharmacokinet 42:293-301.
DJ MJaB (1998) Cytochrome P4502C9: an enzyme of major importance
in human drug metabolism. British Journal of Clinical Pharmacology
45:525-538.
DOH (2001) The Top Ten Diseases cause Death in Taiwan Area, in, The
Department of Health (DOH), Taipei, Taiwan.
Domanski TL, He YA, Harlow GR and Halpert JR (2000) Dual role of
human cytochrome P450 3A4 residue Phe-304 in substrate specificity and
cooperativity. J Pharmacol Exp Ther 293:585-591.
330

Domanski TL, Liu J, Harlow GR and Halpert JR (1998) Analysis of four
residues within substrate recognition site 4 of human cytochrome P450
3A4: role in steroid hydroxylase activity and alpha-naphthoflavone
stimulation. Arch Biochem Biophys 350:223-232.
Dresser GK, Spence JD and Bailey DG (2000a)
Pharmacokinetic-pharmacodynamic consequences and clinical relevance
of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
Dresser GK, Spence JD and Bailey DG (2000b)
Pharmacokinetic-pharmacodynamic consequences and clinical relevance
of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de
Velde V, Mannens G and Edwards DJ (1995a) Itraconazole and
hydroxyitraconazole serum concentrations are reduced more than tenfold
by phenytoin. Clinical Pharmacology & Therapeutics 58:617-624.
Ducharme MP, Warbasse LH and Edwards DJ (1995b) Disposition of
intravenous and oral cyclosporine after administration with grapefruit
juice. Clinical Pharmacology & Therapeutics 57:485-491.
Duggan DE and Vickers S (1990) Physiological disposition of
HMG-CoA-reductase inhibitors. Drug Metab Rev 22:333-362.
331

Echizen H, Kawasaki H, Chiba K, Tani M and Ishizaki T (1993) A potent
inhibitory effect of erythromycin and other macrolide antibiotics on the
mono-N-dealkylation metabolism of disopyramide with human liver
microsomes. Journal of Pharmacology & Experimental Therapeutics
264:1425-1431.
Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I
and Ronn O (1985) Felodipine kinetics in healthy men. Clin Pharmacol
Ther 38:205-211.
Estabrook R, Cooper, D., Rosenthal, O. (1963) The light-reversible
carbon monoxide inhibition of the steroid C-21 hydroxylation system of
the adrenal cortex. Biochem Zeit 338:741-755.
Evans DA (1986) Ethnic differences in reactions to drugs and xenobiotics.
Therapy. Prog Clin Biol Res 214:491-526.
Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY and
Weinstein SH (1991) Biotransformation of pravastatin sodium in humans.
Drug Metabolism & Disposition 19:740-748.
Fahr A (1993) Cyclosporin clinical pharmacokinetics. Clin
Pharmacokinet 24:472-495.
Farrell GC, Cooksley WG and Powell LW (1979) Drug metabolism in
liver disease: activity of hepatic microsomal metabolizing enzymes. Clin
332

Pharmacol Ther 26:483-492.
Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK,
Lovett BD, Nowell PC, Blair IA and Rebbeck TR (1998) Association of
CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci
U S A 95:13176-13181.
Fitzsimmons ME and Collins JM (1997) Selective biotransformation of
the human immunodeficiency virus protease inhibitor saquinavir by
human small-intestinal cytochrome P4503A4: potential contribution to
high first-pass metabolism. Drug Metabolism & Disposition 25:256-266.
Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK and Peters GR
(1996) Biotransformation of tirilazad in human: 2. Effect of ketoconazole
on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther
277:991-998.
Fleming CM, Branch RA, Wilkinson GR and Guengerich FP (1992a)
Human liver microsomal N-hydroxylation of dapsone by cytochrome
P-4503A4. Mol Pharmacol 41:975-980.
Fleming GF, Amato JM, Agresti M and Safa AR (1992b) Megestrol
acetate reverses multidrug resistance and interacts with P-glycoprotein.
Cancer Chemotherapy & Pharmacology 29:445-449.
333

Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I
(1987) Expression of a multidrug-resistance gene in human tumors and
tissues. Proceedings of the National Academy of Sciences of the United
States of America 84:265-269.
Fricker G, Drewe J, Huwyler J, Gutmann H and Beglinger C (1996)
Relevance of p-glycoprotein for the enteral absorption of cyclosporin A:
in vitro-in vivo correlation. British Journal of Pharmacology
118:1841-1847.
Fuhr U and Rost KL (1994) Simple and reliable CYP1A2 phenotyping by
the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics
4:109-116.
Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition
and kinetics of cytochrome P4503A activity in microsomes from rat,
human, and cdna-expressed human cytochrome P450. Drug Metab
Dispos 24:940-947.
Gilad R and Lampl Y (1999) Rhabdomyolysis induced by simvastatin
and ketoconazole treatment. Clin Neuropharmacol 22:295-297.
Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1995)
The effects of ketoconazole on the intestinal metabolism and
bioavailability of cyclosporine. Clinical Pharmacology & Therapeutics
58:15-19.
334

Gonzalez FJ, Kimura S, Tamura S and Gelboin HV (1991) Expression of
mammalian cytochrome P450 using baculovirus. Methods in Enzymology
206:93-99.
Gonzalez FJ and Lee YH (1996) Constitutive expression of hepatic
cytochrome P450 genes. FASEB Journal 10:1112-1117.
Gonzalez FJ, Schmid BJ, Umeno M, McBride OW, Hardwick JP, Meyer
UA, Gelboin HV and Idle JR (1988a) Human P450PCN1: sequence,
chromosome localization, and direct evidence through cDNA expression
that P450PCN1 is nifedipine oxidase. Dna 7:79-86.
Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin
HV and Meyer UA (1988b) Human debrisoquine 4-hydroxylase
(P450IID1): cDNA and deduced amino acid sequence and assignment of
the CYP2D locus to chromosome 22. Genomics 2:174-179.
Gorski JC, Jones DR, Wrighton SA and Hall SD (1994) Characterization
of dextromethorphan N-demethylation by human liver microsomes.
Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Biochemical Pharmacology 48:173-182.
Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance
mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
Greenblatt DJ, Allen MD, Harmatz JS and Shader RI (1980) Diazepam
disposition determinants. Clin Pharmacol Ther 27:301-312.
335

Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Durol AL,
Harrel-Joseph LM and Shader RI (2000) Comparative kinetics and
response to the benzodiazepine agonists triazolam and zolpidem:
evaluation of sex-dependent differences. J Pharmacol Exp Ther
293:435-443.
Greenwood IA and Large WA (1996) Analysis of the time course of
calcium-activated chloride "tail" currents in rabbit portal vein smooth
muscle cells. Pflugers Archiv - European Journal of Physiology
432:970-979.
Grundy SM and Vega GL (1985) Influence of mevinolin on metabolism
of low density lipoproteins in primary moderate hypercholesterolemia.
Journal of Lipid Research 26:1464-1475.
Guengerich FP (1995) Influence of nutrients and other dietary materials
on cytochrome P-450 enzymes. Am J Clin Nutr 61:651S-658S.
Guengerich FP (1999) Inhibition of Drug Metabolizing
Enzymes:Molecular and Biochemical Aspects. Marcel Dekker, New York.
Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C and
Berntsson P (1991) Oxidation of dihydropyridine calcium channel
blockers and analogues by human liver cytochrome P-450 IIIA4. Journal
of Medicinal Chemistry 34:1838-1844.
336

Guengerich FP and MacDonald TL (1990) Mechanisms of cytochrome
P-450 catalysis. Faseb J 4:2453-2459.
Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman
DJ (1986) Characterization of rat and human liver microsomal
cytochrome P-450 forms involved in nifedipine oxidation, a prototype for
genetic polymorphism in oxidative drug metabolism. Journal of
Biological Chemistry 261:5051-5060.
Guengerich FP, Raney KD, Kim DH, Shimada T, Meyer DJ, Ketterer B
and Harris TM (1992) Oxidation and conjugation of aflatoxins by humans
and experimental animals. Progress in Clinical & Biological Research
374:157-165.
Guengerich FP and Shimada T (1991) Oxidation of toxic and
carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical
Research in Toxicology 4:391-407.
Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK,
Watkins PB and Hall SD (1996) Bimodal distribution of renal
cytochrome P450 3A activity in humans. Molecular Pharmacology
50:52-59.
Hagen N, Olsen AK, Andersen JV, Tjornelund J and Hansen SH (2002)
Characterization of mixtures of recombinant human cytochrome p450s as
a screening model for metabolic stability in drug discovery. Xenobiotica
337

32:749-759.
Halpin S and Kingsley D (1993) Disappearance of cerebral calcification
as a sign of tumor growth. AJNR Am J Neuroradiol 14:119-122.
Hansen KT, Thomsen KF and Bundgaard H (1992) Glucuronidation of
the dopamine D-1 receptor antagonists NNC 0756 and NNC 0772 in liver
microsomes. Drug Metab Dispos 20:172-178.
Hardarson A, Sigurdsson G, Olafsdottir E, Dallongeville J, Berg AL and
Arnadottir M (2001) Adrenocorticotrophic hormone exerts marked
lipid-lowering effects in simvastatin-treated patients. J Intern Med
250:530-534.
Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450
3A4 cooperativity: construction and characterization of a site-directed
mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl
Acad Sci U S A 95:6636-6641.
Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM (1994)
Metabolism of taxol by human hepatic microsomes and liver slices:
participation of cytochrome P450 3A4 and an unknown P450 enzyme.
Cancer Research 54:4026-4035.
Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S and
Kamataki T (1993) Gene structure of CYP3A4, an adult-specific form of
338

cytochrome P450 in human livers, and its transcriptional control.
European Journal of Biochemistry 218:585-595.
Hasler JA (1999) Pharmacogenetics of cytochromes P450. Mol Aspects
Med 20:12-24, 25-137.
Hellriegel ET, Bjornsson TD and Hauck WW (1996) Interpatient
variability in bioavailability is related to the extent of absorption:
implications for bioavailability and bioequivalence studies. Clinical
Pharmacology & Therapeutics 60:601-607.
Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and
Kaufmann SH (1992) Effect of P-glycoprotein expression on the
accumulation and cytotoxicity of topotecan (SK&F 104864), a new
camptothecin analogue. Cancer Research 52:2268-2278.
Herman R (1999) Drug interactions and the statins. CMAJ
161:1281-1286.
Hoeg JM and Brewer HB, Jr. (1987) 3-Hydroxy-3- methylglutaryl-
coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
Jama 258:3532-3536.
Hollenberg PF (2002) Characteristics and common properties of
inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev
34:17-35.
339

Horn M (1996) Coadministration of itraconazole with hypolipidemic
agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol
132:1254.
Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH and Kerr BM
(2001) Pharmacokinetic interactions between nelfinavir and
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin
and simvastatin. Antimicrob Agents Chemother 45:3445-3450.
Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright DM and Ward P
(1994) Effect of age and gender on tirilazad pharmacokinetics in humans.
Clin Pharmacol Ther 55:378-384.
Igel M, Sudhop T and von Bergmann K (2001) Metabolism and drug
interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase
inhibitors (statins). Eur J Clin Pharmacol 57:357-364.
Imaoka S, Enomoto K, Oda Y, Asada A, Fujimori M, Shimada T, Fujita S,
Guengerich FP and Funae Y (1990) Lidocaine metabolism by human
cytochrome P-450s purified from hepatic microsomes: comparison of
those with rat hepatic cytochrome P-450s. Journal of Pharmacology &
Experimental Therapeutics 255:1385-1391.
Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich
FP and Abe T (1992) Assignment of the human cytochrome P-450
nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by
340

fluorescence in situ hybridization. Japanese Journal of Human Genetics
37:133-138.
Irshaid Y, Branch RA and Adedoyin A (1996) Metabolic interactions of
putative cytochrome P4503A substrates with alternative pathways of
dapsone metabolism in human liver microsomes. Drug Metab Dispos
24:164-171.
J.H.Lin, I.W. C, M. C, J.A. N and F.A. dL (2000) Route-Dependent
Nonlinear Pharmacokinetics of a Novel HIV Protease Inhibitor:
Involvement of Enzyme Inactivation. Drug Metab Dispos 28:460-466.
Jacobson RH, Wang P and Glueck CJ (1997) Myositis and
rhabdomyolysis associated with concurrent use of simvastatin and
nefazodone. Jama 277:296-297.
Jacolot F, Simon I, Dreano Y, Beaune P, Riche C and Berthou F (1991)
Identification of the cytochrome P450 IIIA family as the enzymes
involved in the N-demethylation of tamoxifen in human liver microsomes.
Biochem Pharmacol 41:1911-1919.
Jalava KM, Olkkola KT and Neuvonen PJ (1997) Itraconazole greatly
increases plasma concentrations and effects of felodipine. Clinical
Pharmacology & Therapeutics 61:410-415.
341

Jones DR, Gorski JC, Haehner BD, O'Mara EM, Jr. and Hall SD (1996)
Determination of cytochrome P450 3A4/5 activity in vivo with
dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374-384.
Jounaidi Y, Hyrailles V, Gervot L and Maurel P (1996) Detection of
CYP3A5 allelic variant: a candidate for the polymorphic expression of
the protein? Biochem Biophys Res Commun 221:466-470.
Kalafsky G, Smith HT and Choc MG (1993) High-performance liquid
chromatographic method for the determination of fluvastatin in human
plasma. J Chromatogr 614:307-313.
Kaminsky LS and Fasco MJ (1991) Small intestinal cytochromes P450.
Critical Reviews in Toxicology 21:407-422.
Kannel W, Castelli W, Gordon T and McNamara P (1971) Serum
cholesterol, lipoproteins and risk of coronary heart disease: the
Framingham study. Ann Interm Med 74:1-12.
Kantola T, Backman JT, Niemi M, Kivisto KT and Neuvonen PJ (2000)
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
Eur J Clin Pharmacol 56:225-229.
Kantola T, Kivisto KT and Neuvonen PJ (1998) Erythromycin and
verapamil considerably increase serum simvastatin and simvastatin acid
concentrations. Clinical Pharmacology & Therapeutics 64:177-182.
342

Kashuba AD, Bertino JS, Jr., Rocci ML, Jr., Kulawy RW, Beck DJ and
Nafziger AN (1998) Quantification of 3-month intraindividual variability
and the influence of sex and menstrual cycle phase on CYP3A activity as
measured by phenotyping with intravenous midazolam. Clin Pharmacol
Ther 64:269-277.
Kawano S, Kamataki T, Yasumori T, Yamazoe Y and Kato R (1987)
Purification of human liver cytochrome P-450 catalyzing testosterone 6
beta-hydroxylation. J Biochem (Tokyo) 102:493-501.
Kenworthy KE, Bloomer JC, Clarke SE and Houston JB (1999) CYP3A4
drug interactions: correlation of 10 in vitro probe substrates. Br J Clin
Pharmacol 48:716-727.
Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J and Kaan A
(1995) Ketoconazole to reduce the need for cyclosporine after cardiac
transplantation. New England Journal of Medicine 333:628-633.
Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ
and Levy RH (1994) Human liver carbamazepine metabolism. Role of
CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical
Pharmacology 47:1969-1979.
Kim AE, Dintaman JM, Waddell DS and Silverman JA (1998) Saquinavir,
an HIV protease inhibitor, is transported by P-glycoprotein. Journal of
Pharmacology & Experimental Therapeutics 286:1439-1445.
343

Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ,
Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ and
Wilkinson GR (1999) Interrelationship between substrates and inhibitors
of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
Kim SG, Williams DE, Schuetz EG, Guzelian PS and Novak RF (1988)
Pyridine induction of cytochrome P-450 in the rat: role of P-450j
(alcohol-inducible form) in pyridine N-oxidation. Journal of
Pharmacology & Experimental Therapeutics 246:1175-1182.
Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L,
Groopman JD, Wilkinson GR and Wood AJ (1993) Absence of
correlations among three putative in vivo probes of human cytochrome
P4503A activity in young healthy men. Clin Pharmacol Ther 54:621-629.
Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood
AJ and Wilkinson GR (1999) Failure of erythromycin breath test to
correlate with midazolam clearance as a probe of cytochrome P4503A.
Clin Pharmacol Ther 66:224-231.
Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kato R and Kanakubo Y
(1985a) Immunochemical examinations of cytochrome P-450 in various
tissues of human fetuses using antibodies to human fetal cytochrome
P-450, P-450 HFLa. Biochem Biophys Res Commun 131:1154-1159.
344

Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kato R and Kanakubo Y
(1985b) Purification and properties of cytochrome P-450 from
homogenates of human fetal livers. Arch Biochem Biophys 241:275-280.
Kivisto KT, Villikka K, Nyman L, Anttila M and Neuvonen PJ (1998)
Tamoxifen and toremifene concentrations in plasma are greatly decreased
by rifampin. Clinical Pharmacology & Therapeutics 64:648-654.
Klaassen CD and Boles JW (1997) Sulfation and sulfotransferases 5: the
importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the
regulation of sulfation. Faseb J 11:404-418.
Klingenberg M (1958) Pigments of rat liver microsomes. Arch Biochem
Biophys 75:376-386.
Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang
XM, Chia D, Terasaki PI, Sabad A, Cogert GA and et al. (1995) Effect of
pravastatin on outcomes after cardiac transplantation. New England
Journal of Medicine 333:621-627.
Kolars JC, Benedict P, Schmiedlin-Ren P and Watkins PB (1994a)
Aflatoxin B1-adduct formation in rat and human small bowel enterocytes.
Gastroenterology 106:433-439.
Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA,
Merion RM and Watkins PB (1994b) CYP3A gene expression in human
345

gut epithelium. Pharmacogenetics 4:247-259.
Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C and Watkins PB (1992)
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human
small bowel enterocytes. Journal of Clinical Investigation 90:1871-1878.
Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie
AE, Gonzalez FJ and Tracy TS (1998) Evaluation of atypical cytochrome
P450 kinetics with two-substrate models: evidence that multiple
substrates can simultaneously bind to cytochrome P450 active sites.
Biochemistry 37:4137-4147.
Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE and
Bierman CW (1982) Altered theophylline clearance during an influenza
B outbreak. Pediatrics 69:476-480.
Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW and
Schwartz JB (1999) In vivo comparison of putative probes of CYP3A4/5
activity: erythromycin, dextromethorphan, and verapamil. Clin
Pharmacol Ther 66:40-50.
Krishna UKaD (1994) Extrahepatic metabolism of drugs in humans.
Clinical Pharmacokinetics 26:144-160.
Krivoruk Y, Kinirons MT, Wood AJ and Wood M (1994) Metabolism of
cytochrome P4503A substrates in vivo administered by the same route:
346

lack of correlation between alfentanil clearance and erythromycin breath
test. Clin Pharmacol Ther 56:608-614.
Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR and
Eichelbaum M (1993) Identification of P450 enzymes involved in
metabolism of verapamil in humans. Naunyn Schmiedebergs Arch
Pharmacol 348:332-337.
Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996)
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor
ritonavir (ABT-538) in human liver microsomes [published erratum
appears in J Pharmacol Exp Ther 1997 Jun;281(3):1506]. Journal of
Pharmacology & Experimental Therapeutics 277:423-431.
Kupfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: a new
drug hydroxylation polymorphism in man. Eur J Clin Pharmacol
26:753-759.
Kupferschmidt HH, Fattinger KE, Ha HR, Follath F and Krahenbuhl S
(1998) Grapefruit juice enhances the bioavailability of the HIV protease
inhibitor saquinavir in man. Br J Clin Pharmacol 45:355-359.
Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J and
Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and
simvastatin acid concentrations. Clin Pharmacol Ther 68:592-597.
347

Lear L, Nation RL and Stupans I (1991) Influence of morphine
concentration on detergent activation of rat liver
morphine-UDP-glucuronosyltransferase. Biochem Pharmacol 42
Suppl:S55-60.
Lechevrel M, Casson AG, Wolf CR, Hardie LJ, Flinterman MB,
Montesano R and Wild CP (1999) Characterization of cytochrome P450
expression in human oesophageal mucosa. Carcinogenesis 20:243-248.
Lefebvre RA, Van Peer A and Woestenborghs R (1997) Influence of
itraconazole on the pharmacokinetics and electrocardiographic effects of
astemizole. Br J Clin Pharmacol 43:319-322.
Li AP, Kaminski DL and Rasmussen A (1995) Substrates of human
hepatic cytochrome P450 3A4. Toxicology 104:1-8.
Lilja JJ, Kivisto KT and Neuvonen PJ (2000) Duration of effect of
grapefruit juice on the pharmacokinetics of the CYP3A4 substrate
simvastatin. Clin Pharmacol Ther 68:384-390.
Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA,
Brown MB, Guo W and Watkins PB (1997a) Grapefruit juice increases
felodipine oral availability in humans by decreasing intestinal CYP3A
protein expression. Journal of Clinical Investigation 99:2545-2553.
348

Lown KS, Ghosh M and Watkins PB (1998) Sequences of intestinal and
hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metabolism &
Disposition 26:185-187.
Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA
and Watkins PB (1994) Interpatient heterogeneity in expression of
CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the
erythromycin breath test. Drug Metabolism & Disposition 22:947-955.
Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK,
Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ and Watkins
PB (1997b) Role of intestinal P-glycoprotein (mdr1) in interpatient
variation in the oral bioavailability of cyclosporine. Clinical
Pharmacology & Therapeutics 62:248-260.
Lundahl J, Regardh CG, Edgar B and Johnsson G (1997) Effects of
grapefruit juice ingestion--pharmacokinetics and haemodynamics of
intravenously and orally administered felodipine in healthy men. Eur J
Clin Pharmacol 52:139-145.
Malingre M, Meerum J, Beijnen J, Huinink W, Rosing H, Koopman F,
Tellingen O, Swart M and Schellens J (2000) Phase I and
Pharmacokinetic Study of Oral Paclitaxel. Journal of Clinical Oncology
18:2468-2475.
349

Malingre M, Meerum J, Beijnen J, Huinink W, Rosing H, Koopman F,
Tellingen O, Swart M and Schellens J (2001) Phase I and
Pharmacokinetic study of bi-daily dosing of Oral Paclitaxell in
combination with cyclosporin A. Cancer Chemother Pharmacol
47:347-354.
Malloy M (1995) Agents Used in Hyperlipidemia. Appleton and Lange,
CT.
Manach C, Morand C, Demigne C, Texier O, Regerat F and Remesy C
(1997) Bioavailability of rutin and quercetin in rats. FEBS Lett
409:12-16.
Markell M, Armenti V, Danovitch C and N. Sumrani (1994)
Hyperlipidemia and glucose intolerance in the post renal transplant
patient. J. Am. Soc. Nephrol. 4:Suppl. S37-S47.
Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J and
Maurel P (1992) Effects of imidazole derivatives on cytochromes P450
from human hepatocytes in primary culture. FASEB Journal 6:752-758.
McKinnon RA and McManus ME (1995) Function and localization of
cytochromes P450 involved in the metabolic activation of food-derived
heterocyclic amines. Princess Takamatsu Symposia 23:145-153.
350

Meerum J, Beijnen J, Rosing H, Koopman F, Tellingen O, Duchin K,
Huinink W, Swart M, Lieverst J and Schellens J (2001a) The effect of
different doses of cyclosporin A on the systemic exposure of orally
administered paclitaxel. Anti-Cancer Drugs 12:351-358.
Meerum J, Beijnen J and Schellens J (2001b) Oral delivery of taxanes.
Investigational New Drugs 19:155-162.
Meerum J, Schellens J, Tellingen O, Ouwehand M, Bardelmeijer H,
Koopman F, Jansen S, Jansen M, Huinink W and Beijnen J (2001c) The
co-solvent Cremophor EL limits absorption of orally administered
paclitaxel in cancer patients. British Journal of Cancer 85:1427-1477.
Meyer UA, Skoda RC and Zanger UM (1990) The genetic polymorphism
of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol
Ther 46:297-308.
Michalets EL (1998) Update: clinically significant cytochrome P-450
drug interactions. Pharmacotherapy 18:84-112.
Min DI, Ku YM, Vichiendilokkul A and Fleckenstein LL (1999) A urine
metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe
for CYP3A activity and prediction of cyclosporine clearance in healthy
volunteers. Pharmacotherapy 19:753-759.
351

Miners BDaJ (1998) Cytochrome P4502C9: an enzyme of major
importance in human drug metabolism. British Journal of Clinical
Pharmacology 45:525-538.
Miniscalco A, Lundahl J, Regardh CG, Edgar B and Eriksson UG (1992a)
Inhibition of dihydropyridine metabolism in rat and human liver
microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp
Ther 261:1195-1199.
Miniscalco A, Lundahl J, Regardh CG, Edgar B and Eriksson UG (1992b)
Inhibition of dihydropyridine metabolism in rat and human liver
microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp
Ther 261:1195-1199.
Mogyorosi A, Bradley B, Showalter A and Schubert ML (1999)
Rhabdomyolysis and acute renal failure due to combination therapy with
simvastatin and warfarin. J Intern Med 246:599-602.
Molowa DT, Schuetz EG, Wrighton SA, Watkins PB, Kremers P,
Mendez-Picon G, Parker GA and Guzelian PS (1986) Complete cDNA
sequence of a cytochrome P-450 inducible by glucocorticoids in human
liver. Proceedings of the National Academy of Sciences of the United
States of America 83:5311-5315.
Morgan ET (1997) Regulation of cytochromes P450 during inflammation
and infection. Drug Metab Rev 29:1129-1188.
352

Mousa O, Brater DC, Sunblad KJ and Hall SD (2000) The interaction of
diltiazem with simvastatin. Clin Pharmacol Ther 67:267-274.
Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT and Burke MD
(1988) The immunocytochemical localisation and distribution of
cytochrome P-450 in normal human hepatic and extrahepatic tissues with
a monoclonal antibody to human cytochrome P-450. British Journal of
Clinical Pharmacology 25:465-475.
Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC and
Melvin WT (1999) Cytochrome P450 CYP3A in human renal cell cancer.
British Journal of Cancer 79:1836-1842.
Murray GI, Taylor MC, Burke MD and Melvin WT (1998) Enhanced
expression of cytochrome P450 in stomach cancer. British Journal of
Cancer 77:1040-1044.
Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga RE, Nucci GD,
Alam SM, Dham R and Qumaruzaman (2003) Pharmacokinetics and
bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and
Zocor) in healthy human volunteers. Biopharm Drug Dispos 24:183-189.
Nation RL, Evans AM and Milne RW (1990a) Pharmacokinetic drug
interactions with phenytoin (Part I). Clin Pharmacokinet 18:37-60.
353

Nation RL, Evans AM and Milne RW (1990b) Pharmacokinetic drug
interactions with phenytoin (Part II). Clin Pharmacokinet 18:131-150.
Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ,
Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W and et al.
(1987a) The P450 gene superfamily: recommended nomenclature. Dna
6:1-11.
Nebert DW and Gonzalez FJ (1987) P450 genes: structure, evolution, and
regulation. Annual Review of Biochemistry 56:945-993.
Nebert DW, Jaiswal AK, Meyer UA and Gonzalez FJ (1987b) Human
P-450 genes: evolution, regulation and possible role in carcinogenesis.
Biochemical Society Transactions 15:586-589.
Nebert DW and McKinnon RA (1994) Cytochrome P450: evolution and
functional diversity. Progress in Liver Diseases 12:63-97.
Nebert DW, McKinnon RA and Puga A (1996) Human
drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and
cancer. DNA & Cell Biology 15:273-280.
Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez
FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B and et al. (1989)
The P450 superfamily: updated listing of all genes and recommended
nomenclature for the chromosomal loci. Dna 8:1-13.
354

Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R,
Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF
and et al. (1991) The P450 superfamily: update on new sequences, gene
mapping, and recommended nomenclature. DNA & Cell Biology 10:1-14.
NECP (1993) Summary of the NCEP Adult Treatment Panel II Report, in
JAMA pp 3015-3023.
Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW,
Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O and et al.
(1993) The P450 superfamily: update on new sequences, gene mapping,
accession numbers, early trivial names of enzymes, and nomenclature.
DNA & Cell Biology 12:1-51.
Neuvonen PJ, Kantola T and Kivisto KT (1998) Simvastatin but not
pravastatin is very susceptible to interaction with the CYP3A4 inhibitor
itraconazole. Clinical Pharmacology & Therapeutics 63:332-341.
Nicholson AN and Stone BM (1982) Performance studies with the
H1-histamine receptor antagonists, astemizole and terfenadine. Br J Clin
Pharmacol 13:199-202.
Nielsen SE, Breinholt V, Justesen U, Cornett C and Dragsted LO (1998)
In vitro biotransformation of flavonoids by rat liver microsomes.
Xenobiotica 28:389-401.
Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F and
Katagiri M (1998) Contribution of human hepatic cytochrome P450
355

isoforms to regioselective hydroxylation of steroid hormones.
Xenobiotica 28:539-547.
NSCLC (2001) A phase II study of weekly oral paclitaxel (Paxoral) with
cyclosporin A (CsA) for advanced non-small cell lung cancer, in
AACR-NCIEORTC International Conference.
Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M and
Kitada M (1998) Differential catalytic properties in metabolism of
endogenous and exogenous substrates among CYP3A enzymes expressed
in COS-7 cells. Biochim Biophys Acta 1380:297-304.
Ohmura T, Sato, R. (1962) A new chytochrome in liver microsomes. J
Biol Chem 237:1375-1376.
Opie L and Frishman W (1995) Lipid-Lowering and Antiatherosclerotic
Drugs. WB Saunder Company, PA.
Ortiz dMPR and MA C (1995) Inhibition of Cytochrome P450 Enzymes.
Plenum Press, New York.
Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL,
Perkins JD and Thummel KE (1997) Characterization of interintestinal
and intraintestinal variations in human CYP3A-dependent metabolism.
Journal of Pharmacology & Experimental Therapeutics 283:1552-1562.
356

Palamanda J, Feng W, Lin C and Nomeir A (2000) Stimulation of
tolbutamide hydroxylation by acetone and acetonitrile in human liver
microsomes and in a cytochrome P-450 2C9-reconstituted system. Drug
Metab Dispos 28.
Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP and
Yang CS (1993) Cytochrome P450 enzymes involved in acetaminophen
activation by rat and human liver microsomes and their kinetics.
Chemical Research in Toxicology 6:511-518.
Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS
(1990) Hydroxylation of chlorzoxazone as a specific probe for human
liver cytochrome P-450IIE1. Chemical Research in Toxicology
3:566-573.
Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H and Maurel P (1992)
Effect of corticosteroids on the expression of cytochromes P450 and on
cyclosporin A oxidase activity in primary cultures of human hepatocytes.
Molecular Pharmacology 41:1047-1055.
Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and
Maurel P (1990a) Cyclosporin A drug interactions. Screening for
inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in
primary cultures of human hepatocytes and in liver microsomes. Drug
Metabolism & Disposition 18:595-606.
357

Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot JP and
Maurel P (1990b) Identification of the rabbit and human cytochromes
P-450IIIA as the major enzymes involved in the N-demethylation of
diltiazem. Drug Metabolism & Disposition 18:711-719.
Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter
DE, Arison BH and Vyas KP (1997a) In vitro metabolism of simvastatin
in humans [SBT]identification of metabolizing enzymes and effect of the
drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter
DE, Arison BH and Vyas KP (1997b) In vitro metabolism of simvastatin
in humans [SBT]identification of metabolizing enzymes and effect of the
drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
Prueksaritanont T, Ma B, Fang X, Subramanian R, Yu J and Lin JH (2001)
beta-Oxidation of simvastatin in mouse liver preparations. Drug Metab
Dispos 29:1251-1255.
Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ,
Lin JH and Baillie TA (1999) Metabolic interactions between mibefradil
and HMG-CoA reductase inhibitors: an in vitro investigation with human
liver preparations. Br J Clin Pharmacol 47:291-298.
Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH,
Pearson PG and Baillie TA (2002) Glucuronidation of statins in animals
358

and humans: a novel mechanism of statin lactonization. Drug Metab
Dispos 30:505-512.
Puig JF and Tephly TR (1986) Isolation and purification of rat liver
morphine UDP-glucuronosyltransferase. Mol Pharmacol 30:558-565.
Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E and Mackenzie
PI (1999) Structural and functional studies of
UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt
J and Brosen K (1995) Selective serotonin reuptake inhibitors and
theophylline metabolism in human liver microsomes: potent inhibition by
fluvoxamine. British Journal of Clinical Pharmacology 39:151-159.
Rebbeck TR, Jaffe JM, Walker AH, Wein AJ and Malkowicz SB (1998)
Modification of clinical presentation of prostate tumors by a novel
genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229.
Regardh CG, Heggelund A, Kylberg-Hanssen K and Lundborg P (1990)
Pharmacokinetics of pafenolol after i.v. and oral administration of three
separate doses of different strength to man. Biopharm Drug Dispos
11:607-617.
Rehman MA, al-Sulaiman MH, Mousa DH, al-Hawas FA, Abdalla AH,
Rassoul Z and al-Khader AA (1995) Effects of simvastatin in
hyperlipidemic renal transplant patients receiving cyclosporine.
359

Transplantation 60:397-399.
Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ and
Korzekwa KR (1994) O-demethylation of epipodophyllotoxins is
catalyzed by human cytochrome P450 3A4. Molecular Pharmacology
45:352-358.
Renwick A (2001) Toxicokinetics: Pharmacokinetics in Toxicology.
Raven Press, New York.
Rivory LP, Qin H, Clarke SJ, Eris J, Duggin G, Ray E, Trent RJ and
Bishop JF (2000) Frequency of cytochrome P450 3A4 variant genotype
in transplant population and lack of association with cyclosporin
clearance. Eur J Clin Pharmacol 56:395-398.
Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping:
attempting to bridge the gap between cDNA-expressed cytochromes P450
and native human liver microsomes. Biochem Pharmacol 57:465-480.
Rodrigues AD, Roberts EM, Mulford DJ, Yao Y and Ouellet D (1997)
Oxidative metabolism of clarithromycin in the presence of human liver
microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Drug Metab Dispos 25:623-630.
Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H,
Crespi CL and Gonzalez FJ (2000) CYP3A4 allelic variants with amino
360

acid substitutions in exons 7 and 12: evidence for an allelic variant with
altered catalytic activity. Clinical Pharmacology & Therapeutics
67:48-56.
Sattler M, Guengerich FP, Yun CH, Christians U and Sewing KF (1992)
Cytochrome P-450 3A enzymes are responsible for biotransformation of
FK506 and rapamycin in man and rat. Drug Metabolism & Disposition
20:753-761.
Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J and
Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin
with mibefradil. Lancet 351:1929-1930.
Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX,
Karsov D and Shader RI (1996) Characterization of six in vitro reactions
mediated by human cytochrome P450: application to the testing of
cytochrome P450-directed antibodies. Pharmacology 52:125-134.
Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS and Shader RI
(1995) N-demethylation of amitriptyline in vitro: role of cytochrome
P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. Journal
of Pharmacology & Experimental Therapeutics 275:592-597.
Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS,
Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF and
Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4
361

substrates by grapefruit constituents. Decreased enterocyte CYP3A4
concentration and mechanism-based inactivation by furanocoumarins.
Drug Metabolism & Disposition 25:1228-1233.
Schoene B, Fleischmann RA, Remmer H and von Oldershausen HF
(1972) Determination of drug metabolizing enzymes in needle biopsies of
human liver. Eur J Clin Pharmacol 4:65-73.
Schuetz EG, Beck WT and Schuetz JD (1996a) Modulators and
substrates of P-glycoprotein and cytochrome P4503A coordinately
up-regulate these proteins in human colon carcinoma cells. Molecular
Pharmacology 49:311-318.
Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G,
Raucy J, Guzelian P, Gionela K and Watlington CO (1992) Expression of
cytochrome P450 3A in amphibian, rat, and human kidney. Archives of
Biochemistry & Biophysics 294:206-214.
Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa
DT, Li D and Guzelian PS (1993) Regulation of human liver cytochromes
P-450 in family 3A in primary and continuous culture of human
hepatocytes. Hepatology 18:1254-1262.
Schuetz JD, Beach DL and Guzelian PS (1994) Selective expression of
cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.
Pharmacogenetics 4:11-20.
362

Schuetz JD, Molowa DT and Guzelian PS (1989) Characterization of a
cDNA encoding a new member of the glucocorticoid-responsive
cytochromes P450 in human liver. Archives of Biochemistry & Biophysics
274:355-365.
Schuetz JD, Schuetz EG, Thottassery JV, Guzelian PS, Strom S and Sun
D (1996b) Identification of a novel dexamethasone responsive enhancer
in the human CYP3A5 gene and its activation in human and rat liver cells.
Molecular Pharmacology 49:63-72.
Segaert MF, De Soete C, Vandewiele I and Verbanck J (1996)
Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant
11:1846-1847.
Segel I (1975) Enzyme Kinetics: Behavior and Analysis of Rapid
Equilibrium and Steady-State Enzyme Systems. Wiley and Sons, New
York.
Shaw PM, Barnes TS, Cameron D, Engeset J, Melvin WT, Omar G,
Petrie JC, Rush WR, Snyder CP, Whiting PH and et al. (1989)
Purification and characterization of an anticonvulsant-induced human
cytochrome P-450 catalysing cyclosporin metabolism. Biochem J
263:653-663.
Shimada T, Gillam EM, Sandhu P, Guo Z, Tukey RH and Guengerich FP
(1994a) Activation of procarcinogens by human cytochrome P450
363

enzymes expressed in Escherichia coli. Simplified bacterial systems for
genotoxicity assays. Carcinogenesis 15:2523-2529.
Shimada T, Iwasaki M, Martin MV and Guengerich FP (1989) Human
liver microsomal cytochrome P-450 enzymes involved in the
bioactivation of procarcinogens detected by umu gene response in
Salmonella typhimurium TA 1535/pSK1002. Cancer Research
49:3218-3228.
Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994b)
Interindividual variations in human liver cytochrome P-450 enzymes
involved in the oxidation of drugs, carcinogens and toxic chemicals:
studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal
of Pharmacology & Experimental Therapeutics 270:414-423.
Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin
HV and Korzekwa KR (1994) Activation of CYP3A4: evidence for the
simultaneous binding of two substrates in a cytochrome P450 active site.
Biochemistry 33:6450-6455.
Simard C, O'Hara GE, Prevost J, Guilbaud R, Massee R and Turgeon J
(2001) Study of the drug-drug interaction between simvastatin and
cisapride in man. Eur J Clin Pharmacol 57:229-234.
Slaughter DEaR (1995) Recent advances: the cytochrome P450 enzymes.
The Annals of Pharmacotherapy 26.
364

Smith DA and Jones BC (1992) Speculations on the substrate
structure-activity relationship (SSAR) of cytochrome P450 enzymes.
Biochem Pharmacol 44:2089-2098.
Smith SJ, Korzekwa KR, Aoyama T, Gonzalez FJ, Darbyshire JF,
Sugiyama K and Gillette JR (1992) 12 alpha-hydroxytestosterone. A
hitherto unidentified testosterone metabolite produced by cytochrome
P-450 2A2. Drug Metabolism & Disposition 20:566-571.
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer
DK, Borst P, Nooijen WJ, Beijnen JH and van Tellingen O (1997)
Limited oral bioavailability and active epithelial excretion of paclitaxel
(Taxol) caused by P-glycoprotein in the intestine. Proceedings of the
National Academy of Sciences of the United States of America
94:2031-2035.
Spina E, Pisani F and Perucca E (1996) Clinically significant
pharmacokinetic drug interactions with carbamazepine. An update. Clin
Pharmacokinet 31:198-214.
Stein CM, Kinirons MT, Pincus T, Wilkinson GR and Wood AJ (1996)
Comparison of the dapsone recovery ratio and the erythromycin breath
test as in vivo probes of CYP3A activity in patients with rheumatoid
arthritis receiving cyclosporine. Clinical Pharmacology & Therapeutics
59:47-51.
365

Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K,
Arakawa M, Sakamoto K, Masada M, Miyamori I and Fujimura A (2001)
Different effects of St John's wort on the pharmacokinetics of simvastatin
and pravastatin. Clin Pharmacol Ther 70:518-524.
Tanaka E (1998) In vivo age-related changes in hepatic drug-oxidizing
capacity in humans. J Clin Pharm Ther 23:247-255.
Tateishi T, Nakura H, Asoh M, Watanabe M, Tanaka M, Kumai T,
Takashima S, Imaoka S, Funae Y, Yabusaki Y, Kamataki T and
Kobayashi S (1997a) A comparison of hepatic cytochrome P450 protein
expression between infancy and postinfancy. Life Sciences 61:2567-2574.
Tateishi T, Soucek P, Caraco Y, Guengerich FP and Wood AJ (1997b)
Colchicine biotransformation by human liver microsomes. Identification
of CYP3A4 as the major isoform responsible for colchicine
demethylation. Biochemical Pharmacology 53:111-116.
Tepsuwan A, Kupradinun P and Kusamran WR (1999) Effect of Siamese
cassia leaves on the activities of chemical carcinogen metabolizing
enzymes and on mammary gland carcinogenesis in the rat. Mutat Res
428:363-373.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and
Willingham MC (1987) Cellular localization of the multidrug-resistance
366

gene product P-glycoprotein in normal human tissues. Proceedings of the
National Academy of Sciences of the United States of America
84:7735-7738.
Thummel KE DS, TD Podoll, KL Kunze, WF Trager, PS Hartwell, VA
Raisys, CL Marsh, JP McVicar, DM Barr (1994) Use of midazolam as a
human cytochrome P450 3A probe:I. In vitro-in vivo correlations in liver
transplant patients. J Pharmacol Exp Ther 271:549-556.
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE,
Marsh CL, McVicar JP, Barr DM, Perkins JD and et al. (1994a) Use of
midazolam as a human cytochrome P450 3A probe: II. Characterization
of inter- and intraindividual hepatic CYP3A variability after liver
transplantation. J Pharmacol Exp Ther 271:557-566.
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS,
Raisys VA, Marsh CL, McVicar JP, Barr DM and et al. (1994b) Use of
midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo
correlations in liver transplant patients. J Pharmacol Exp Ther
271:549-556.
Todd PA and Goa KL (1990) Simvastatin. A review of its
pharmacological properties and therapeutic potential in
hypercholesterolaemia. Drugs 40:583-607.
Toffoli G FSaMG, , (1994) Comparison of mechanisms responsible for
367

esistance to idarubicin and daunorubicin in multidrug resistance Lo Vo
cell lines. Biochem Pharmacol 48:1871-1881.
Toreson H and Eriksson BM (1996) Determination of fluvastatin
enantiomers and the racemate in human blood plasma by liquid
chromatography and fluorometric detection. J Chromatogr A 729:13-18.
Trivier JM, Libersa C, Belloc C and Lhermitte M (1993) Amiodarone
N-deethylation in human liver microsomes: involvement of cytochrome
P450 3A enzymes (first report). Life Sci 52:L91-96.
Ueng YF, Kuwabara T, Chun YJ and Guengerich FP (1997)
Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
Biochemistry 36:370-381.
Venkatesan K (1992) Pharmacokinetic drug interactions with rifampicin.
Clin Pharmacokinet 22:47-65.
Vickers S, Duncan CA, Chen IW, Rosegay A and Duggan DE (1990a)
Metabolic disposition studies on simvastatin, a cholesterol-lowering
prodrug. Drug Metab Dispos 18:138-145.
Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit
HG, Pitzenberger SM, Stokker G and Duggan DE (1990b) In vitro and in
vivo biotransformation of simvastatin, an inhibitor of HMG CoA
reductase. Drug Metab Dispos 18:476-483.
368

Villeneuve JP, L'Ecuyer L, De Maeght S and Bannon P (2000) Prediction
of cyclosporine clearance in liver transplant recipients by the use of
midazolam as a cytochrome P450 3A probe. Clin Pharmacol Ther
67:242-248.
Vincent J, Meredith PA, Reid JL, Elliott HL and Rubin PC (1985)
Clinical pharmacokinetics of prazosin--1985. Clinical Pharmacokinetics
10:144-154.
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE and
Shader RI (1996) Inhibition of terfenadine metabolism in vitro by azole
antifungal agents and by selective serotonin reuptake inhibitor
antidepressants: relation to pharmacokinetic interactions in vivo [see
comments]. Journal of Clinical Psychopharmacology 16:104-112.
Wacher VJ, Silverman JA, Zhang Y and Benet LZ (1998) Role of
P-glycoprotein and cytochrome P450 3A in limiting oral absorption of
peptides and peptidomimetics. Journal of Pharmaceutical Sciences
87:1322-1330.
Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate
specificities and tissue distribution of cytochrome P450 3A and
P-glycoprotein: implications for drug delivery and activity in cancer
chemotherapy. Molecular Carcinogenesis 13:129-134.
369

Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ and Wilkinson GR
(2000) CYP3A activity in African American and European American
men: population differences and functional effect of the
CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther
68:82-91.
Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP and Vyas KP
(1991) Biotransformation of lovastatin. IV. Identification of cytochrome
P450 3A proteins as the major enzymes responsible for the oxidative
metabolism of lovastatin in rat and human liver microsomes. Archives of
Biochemistry & Biophysics 290:355-361.
Wanner C, Bartens W and Galle J (1995) Clinical utility of antilipidemic
therapies in chronic renal allograft failure. Kidney International
Supplement 52:S60-62.
Warrington JS, Shader RI, von Moltke LL and Greenblatt DJ (2000) In
vitro biotransformation of sildenafil (Viagra): identification of human
cytochromes and potential drug interactions. Drug Metab Dispos
28:392-397.
Watkins PB (1990) The role of cytochromes P-450 in cyclosporine
metabolism. Journal of the American Academy of Dermatology
23:1301-1309.
370

Watkins PB, Murray SA, Thomas PE and Wrighton SA (1990)
Distribution of cytochromes P-450, cytochrome b5, and
NADPH-cytochrome P-450 reductase in an entire human liver.
Biochemical Pharmacology 39:471-476.
Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA
and Guzelian PS (1989) Erythromycin breath test as an assay of
glucocorticoid-inducible liver cytochromes P-450. Studies in rats and
patients. Journal of Clinical Investigation 83:688-697.
Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T,
Fishman K, Guzelian PS and Voorhees JJ (1992) Comparison of urinary
6-beta-cortisol and the erythromycin breath test as measures of hepatic
P450IIIA (CYP3A) activity. Clinical Pharmacology & Therapeutics
52:265-273.
Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G,
Parker GA and Guzelian PS (1985) Identification of an inducible form of
cytochrome P-450 in human liver. Proceedings of the National Academy
of Sciences of the United States of America 82:6310-6314.
Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS
(1987) Identification of glucocorticoid-inducible cytochromes P-450 in
the intestinal mucosa of rats and man. Journal of Clinical Investigation
80:1029-1036.
371

Waxman DJ, Attisano C, Guengerich FP and Lapenson DP (1988)
Human liver microsomal steroid metabolism: identification of the major
microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450
enzyme. Arch Biochem Biophys 263:424-436.
Weise WJ and Possidente CJ (2000) Fatal rhabdomyolysis associated
with simvastatin in a renal transplant patient. Am J Med 108:351-352.
Westlind A, Lofberg L, Tindberg N, Andersson TB and
Ingelman-Sundberg M (1999) Interindividual differences in hepatic
expression of CYP3A4: relationship to genetic polymorphism in the
5'-upstream regulatory region. Biochem Biophys Res Commun
259:201-205.
White MCaR (1980) Oxygen activation by cytochrome P450. Annual
Reveiw of Biochemistry 49:315-356.
Wilkinson GR, Guengerich FP and Branch RA (1989) Genetic
polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther
43:53-76.
Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ and
Scherman D (1994) Polarized transport of docetaxel and vinblastine
mediated by P-glycoprotein in human intestinal epithelial cell monolayers.
Biochemical Pharmacology 48:1528-1530.
Wingard (1991) Lipid-Lowering Drugs and Atherosclerosis. Wolfe
372

Publishing Ltd, London.
Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL,
Molowa DT and Vandenbranden M (1990) Studies on the expression and
metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Molecular Pharmacology 38:207-213.
Wrighton SA and Elswick B (1989) Modulation of the induction of rat
hepatic cytochromes P-450 by selenium deficiency. Biochemical
Pharmacology 38:3767-3771.
Wrighton SA, Ring BJ, Watkins PB and VandenBranden M (1989)
Identification of a polymorphically expressed member of the human
cytochrome P-450III family. Molecular Pharmacology 36:97-105.
Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and
Wacher VJ (1995) Differentiation of absorption and first-pass gut and
hepatic metabolism in humans: studies with cyclosporine. Clinical
Pharmacology & Therapeutics 58:492-497.
Yamazaki H and Shimada T (1997) Progesterone and testosterone
hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver
microsomes. Archives of Biochemistry & Biophysics 346:161-169.
Yamazaki H and Shimada T (1998) Comparative studies of in vitro
inhibition of cytochrome P450 3A4-dependent testosterone
6beta-hydroxylation by roxithromycin and its metabolites,
373

troleandomycin, and erythromycin. Drug Metabolism & Disposition
26:1053-1057.
Yang HY, Lee QP, Rettie AE and Juchau MR (1994) Functional
cytochrome P4503A isoforms in human embryonic tissues: expression
during organogenesis. Mol Pharmacol 46:922-928.
Yue Q, von Bahr C, Odar-Cederlof I and Sawe J (1990) Glucuronidation
of codeine and morphine in human liver and kidney microsomes: effect
of inhibitors. Pharmacol Toxicol 66:221-226.
Yue QY and Sawe J (1997) Different effects of inhibitors on the O- and
N-demethylation of codeine in human liver microsomes. Eur J Clin
Pharmacol 52:41-47.
Yun CH, Okerholm RA and Guengerich FP (1993) Oxidation of the
antihistaminic drug terfenadine in human liver microsomes. Role of
cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug
Metabolism & Disposition 21:403-409.
Yun CH, Wood M, Wood AJ and Guengerich FP (1992) Identification of
the pharmacogenetic determinants of alfentanil metabolism: cytochrome
P-450 3A4. An explanation of the variable elimination clearance.
Anesthesiology 77:467-474.
Zhang W, Y R, T K, H N, RF T and EM S (2002) Inhibition of
374

cytochromes P450 by antifungal imidazole derivatives. Drug Metab
Dispos 30:314-318.
Zhi J, Moore R, Kanitra L and Mulligan TE (2003) Effects of orlistat, a
lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs
(amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin
Pharmacol 43:428-435.
Ziviani L, Da Ros L, Squassante L, Milleri S, Cugola M and Iavarone LE
(2001) The effects of lacidipine on the steady/state plasma concentrations
of simvastatin in healthy subjects. Br J Clin Pharmacol 51:147-152.
Zou L, Harkey MR and Henderson GL (2002) Effects of herbal
components on cDNA-expressed cytochrome P450 enzyme catalytic
activity. Life Sci 71:1579-1589.
375